EFECTOS DEL TRATAMIENTO CON RALOXIFENO O CON ESTROGENOS MAS PROGESTERONA SOBRE LOS PREDICTORES DE ENFERMEDAD VASCULAR ATEROTROMBOTICA EN MUJERES POSMENOPAUSICAS SANAS. INTERPRETACIÓN DE LOS DATOS EN EL CONTEXTO DE LOS ESTUDIOS HERS Y WHI
Columnista Experta de SIIC Pamela W. Anderson
en colaboración con
David A Cox
Fecha de aprobación: 21 de Octubre, 2003
Primera edición en siicsalud:
10 de Diciembre, 2003
Sección Artículos originales,
subsección
Expertos del Mundo,
página
http://www.siicsalud.com/des/des035/03d09000.htm
Especialidad principal:
 .
Especialidades relacionadas:
 Cardiología, Epidemiología, Medicina Farmacéutica, Farmacología, Medicina Interna, Obstetricia y Ginecología, Endocrinología y Metabolismo.
|
Anderson PW, Draper MW. 1997. Raloxifene—A novel selective receptor modulator (SERM) with potential cardioprotective effects in the postmenopausal woman
Clin Calcium
7:93-97, 1997
Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS, Anderson PW. 1998. The effects of raloxifene HCl on serum lipids and coagulation factors in healthy postmenopausal women
JAMA
279:1445-1451, 1998
Walsh BW, Paul S, Wild RA, Dean RA, Tracy RP, Cox DA, Anderson PW. 2000. The effects of raloxifene compared with hormone replacement therapy on homocysteine and C-reactive protein in healthy postmenopausal women: a randomized, controlled trial
J Clin Endo Metab
85:214-218, 2000
Anderson PW, Cox DA, Sashegyi A, Paul S, Silfen SL,Walsh BW. 2001. Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women.
Maturitas
39:71-77, 2001
Mosca L, Barrett-Connor E, Wenger NK, Collins P, Grady D, Kornitzer M, Moscarelli E, Paul S, Wright T, Helterbrand J, Anderson PW. 2001. Design and methods of the Raloxifene Use For the Heart (RUTH) study
Amer J Cardiol
88:392-395, 2001
Walsh BW, Cox DA, Sashegyi A, Dean RA, Tracy RP, Anderson PW. 2001. Role of tumor necrosis factor-beta and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women
Am J Cardiology
88:825-828, 2001
Mosca L, Harper K, Sarkar S, O\'Gorman J, Anderson PW, Cox DA, Barrett-Connor E. 2001. Effect of raloxifene on serum triglycerides in postmenopausal women: Influence of predisposing factors for hypertriglyceridemia
Clin Ther
23(1552-1565), 2001
Andersson B, Johannsson G, Holm G, Bengtsson B-A, Sashegyi A, Pavo I, Mason T, Anderson PW. 2002. Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: A randomized clinical trial
J Clin Endo and Metab
87:122-128, 2002
Andersson B, Johannsson G, Holm G, Bengtsson B-A, Sashegyi A, Pavo I, Mason T, Anderson PW. 2002. Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: A randomized clinical trial
, 0
Andersson B, Johannsson G, Holm G, Bengtsson B-A, Sashegyi A, Pavo I, Mason T, Anderson PW. 2002. Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: A randomized clinical trial
, 0
Dr. Pamela W. Anderson
Dirección profesional:
Pamela W. Anderson, MD. Lilly Corporate Center DC6161, Indianápolis, IN 46285
|
